BRPI0412989A - combinação farmacêutica útil para mobilização de célula-tronco - Google Patents

combinação farmacêutica útil para mobilização de célula-tronco

Info

Publication number
BRPI0412989A
BRPI0412989A BRPI0412989-0A BRPI0412989A BRPI0412989A BR PI0412989 A BRPI0412989 A BR PI0412989A BR PI0412989 A BRPI0412989 A BR PI0412989A BR PI0412989 A BRPI0412989 A BR PI0412989A
Authority
BR
Brazil
Prior art keywords
stem cell
pharmaceutical combination
cell mobilization
combination useful
useful
Prior art date
Application number
BRPI0412989-0A
Other languages
English (en)
Inventor
Alessandro Massimo Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of BRPI0412989A publication Critical patent/BRPI0412989A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMBINAçãO FARMACêUTICA úTIL PARA MOBILIZAçãO DE CéLULA-TRONCO". A presente invenção refere-se a preparação farmacêutica combinada contendo G-CSF e PIGF como as substâncias ativas é útil na mobilização de células-tronco sangüíneas em um paciente ou indivíduo com necessidade das mesmas.
BRPI0412989-0A 2003-07-29 2004-07-23 combinação farmacêutica útil para mobilização de célula-tronco BRPI0412989A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017174 2003-07-29
PCT/EP2004/008245 WO2005014023A1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell

Publications (1)

Publication Number Publication Date
BRPI0412989A true BRPI0412989A (pt) 2006-10-03

Family

ID=34130041

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412989-0A BRPI0412989A (pt) 2003-07-29 2004-07-23 combinação farmacêutica útil para mobilização de célula-tronco

Country Status (21)

Country Link
US (1) US20070036747A1 (pt)
EP (1) EP1660115B1 (pt)
JP (1) JP4855253B2 (pt)
KR (1) KR101192136B1 (pt)
CN (1) CN100534528C (pt)
AT (1) ATE513555T1 (pt)
AU (1) AU2004262909B2 (pt)
BR (1) BRPI0412989A (pt)
CA (1) CA2526244C (pt)
DK (1) DK1660115T3 (pt)
ES (1) ES2369487T3 (pt)
IL (1) IL173369A (pt)
MX (1) MXPA06000017A (pt)
NO (1) NO20060955L (pt)
NZ (1) NZ543612A (pt)
PL (1) PL1660115T3 (pt)
PT (1) PT1660115E (pt)
RU (1) RU2351357C2 (pt)
SI (1) SI1660115T1 (pt)
WO (1) WO2005014023A1 (pt)
ZA (1) ZA200509361B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
SI1853619T1 (sl) 2005-03-02 2011-01-31 Univ Maryland 3-beta-hidroksi-17-(1H-benzmidazol-1-il)androsta-5,16-dien za uporabo pri zdravljenju bolezni prostate
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
WO2009129208A2 (en) 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
CA2770092A1 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
KR102503695B1 (ko) 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 동원하기 위한 방법 및 조성물
WO2014153215A1 (en) 2013-03-14 2014-09-25 University Of Maryland,Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
CN114891746A (zh) * 2021-12-21 2022-08-12 青岛今墨堂生物技术有限公司 一种犬全血造血干细胞的制备方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
EP1594527A2 (en) * 2003-02-04 2005-11-16 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells

Also Published As

Publication number Publication date
DK1660115T3 (da) 2011-10-10
NO20060955L (no) 2006-02-27
RU2351357C2 (ru) 2009-04-10
ZA200509361B (en) 2007-03-28
PL1660115T3 (pl) 2011-11-30
KR20060079753A (ko) 2006-07-06
IL173369A (en) 2010-12-30
CA2526244A1 (en) 2005-02-17
CN100534528C (zh) 2009-09-02
SI1660115T1 (sl) 2011-10-28
EP1660115A1 (en) 2006-05-31
MXPA06000017A (es) 2006-03-21
RU2006106228A (ru) 2007-09-10
JP4855253B2 (ja) 2012-01-18
JP2007500157A (ja) 2007-01-11
WO2005014023A1 (en) 2005-02-17
AU2004262909A1 (en) 2005-02-17
KR101192136B1 (ko) 2012-10-16
PT1660115E (pt) 2011-08-24
EP1660115B1 (en) 2011-06-22
NZ543612A (en) 2008-03-28
CN1826134A (zh) 2006-08-30
IL173369A0 (en) 2006-06-11
CA2526244C (en) 2012-03-20
ATE513555T1 (de) 2011-07-15
AU2004262909B2 (en) 2010-07-01
US20070036747A1 (en) 2007-02-15
ES2369487T3 (es) 2011-12-01

Similar Documents

Publication Publication Date Title
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
WO2002028999A3 (en) Gene expression profiles in granulocytic cells
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
NO20064584L (no) Tetrahydropyridoindolderivater
DK1682446T3 (da) Lithiummetalphosphater, fremgangsmåde til deres fremstilling og anvendelse som elektrodematerialer
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
EA200602137A1 (ru) Гидрогелевые препараты интерферона
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
FR2883184B1 (fr) Composition de spirulines riche en principes actifs, procede d'obtention et utilisation
GT200200279A (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
SE0300457D0 (sv) Novel compounds
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
IL169687A0 (en) Methods for the drug prophylaxis of poisoning by cholinesterase inhibitors, and active ingredients and medicaments suitable therefore
NL1022442C2 (nl) Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
DE602005001505D1 (de) Etherderivate, deren herstellung und deren verwendung als pharmazeutische mittel
WO2004087117A3 (de) Verwendung von cyclischen aketalen/ketalen zur verbesserten penetration von wirkstoffen in zellen und organen

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DOMPE' S.P.A. (IT)

Free format text: TRANSFERIDO POR FUSAO DE: DOMPE PHA.R.MA S.P.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.